Entellus Launches New Sinus Treatment Device; Prepares To Release Data From Randomized Study
Executive Summary
While launching a new balloon-based device to treat chronic sinusitis, Entellus Medical Inc. revealed it would release details on an important clinical study in July.
You may also be interested in...
Washington Roundup, February 2013
The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.”
Companies See Opportunities In Expanding ENT Market
Competition breeds innovation, and the ear, nose, and throat (ENT) market, once a fairly quiet arena, is now positioned to host some spirited activity that should lead to new technologies. Several large device manufacturers have recently moved into the ENT space, and the sinus treatment segment of the market has become one of the focal points for emerging competitors, as companies work toward less-invasive treatment options.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.